Navigation Links
Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
Date:6/18/2008

NEW YORK, June 18 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals (AMEX: IMM) and Beijing Capital Medical University (BCMU) in Beijing, one of China's leading academic medical research centers, today announced that they have signed a Memorandum of Understanding to develop a joint venture to provide contract research services (CRS) in China. The joint venture will provide a range of services in drug discovery research for international companies and research organizations seeking to develop and market pharmaceutical products and biologics.

"Immtech brings extensive experience in clinical development programs conducted at multiple sites around the world to our joint venture with BCMU, which ranks among the top academic medical institutions in China. By combining our complementary resources and expertise, we will deliver high-quality research services that will help companies to reduce the time and costs associated with drug discovery," said Eric L. Sorkin, Chairman and Chief Executive Officer of Immtech.

The joint venture will be established later this year and will provide services ranging from research planning and risk assessment through preclinical and clinical study design. With an initial focus on early-stage drug discovery, the joint venture will also be positioned to support later-stage clinical development including coordination with research sites, data management, monitoring and reporting for clinical research programs. Expansion of the joint venture's operation will include providing counsel and support related to clinical research regulatory guidelines and regulatory review procedures in China.

"As the world's most rapidly expanding market for healthcare products, China is poised for explosive growth in re
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Immtech Appoints Blythe Weigh as Strategic Advisor
2. Immtech Reports Fiscal Third Quarter 2008 Results
3. Immtech Investor Conference Call Scheduled for February 11, 2008
4. Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine
5. Immtech to Present at The Bank of Montreal Healthcare Conference
6. Synovics Pharmaceuticals Announces Continued Growth of Customer Relationships
7. GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives
8. Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
9. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
11. Fontus Pharmaceuticals Acquires Nephrology and Endocrinology Drug from Roche Laboratories Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 16, 2014 The Activated Carbon ... which is why IBISWorld updated its original industry research ... benefit from an intensified focus on environmental policy. Over ... emission standards for power plants and a range of ... IBISWorld Industry Analyst Sarah Kahn, “a range of downstream ...
(Date:12/17/2014)... Once more, EMAAR has selected ... waste water treatment plant to phase one of BayLaSun, ... Two years ago Bioshaft successfully supplied and operated a ... residential towers with an occupancy of 900 residences. ... gallons per day and was signed on September 16th, ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce ... V19 with PVM technology , is now available. ... measurement tool continuously captures high-resolution images under a ... automatically prepares a report pairing the most relevant ... changes. This compelling blend of high resolution images ...
Breaking Biology Technology:Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... (NYSE: CVD ) today reported GAAP earnings ... $0.35 per diluted share.  Included in fourth quarter results ... $0.10 of which relates to the completion of the ... the termination of a research products inventory supply agreement ...
... at the University of California, Riverside has identified a property ... to finding the Higgs boson in particle physics. Graphene, ... carbon atoms arranged in a hexagonal lattice. Because of ... themselves well to stacking. BLG is formed ...
... 2012 SPO Medical Inc. ( SPOM ... for use in portable monitoring devices, announced today an ... revenue generation strategy for fiscal 2012 primarily based on ... range of consumer wellness devices. SPO currently ...
Cached Biology Technology:Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 2Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 3Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 4Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 5Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 6Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 7Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 8Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 9Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 10Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 11Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 12Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 13Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 14Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M 15Bilayer graphene works as an insulator 2Bilayer graphene works as an insulator 3SPO Updates Shareholders on 2012 Corporate Strategy 2SPO Updates Shareholders on 2012 Corporate Strategy 3
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... the global "green" trend, educators worldwide are relying ... science knowledge. Studies have revealed that bringing environmental ... scoresenvironmental-based lessons can also improve student test scores ... in developing new ways to integrate these relevant ...
... collectively weigh and initiate different survival strategies say they ... decisions that affect their health, wealth and the fate ... week in the early online edition of the journal ... was accomplished when the scientists applied the mathematical techniques ...
... French . , Montreal, December 11, 2009 ... prevents cancer. In the December 11 edition of the prestigious ... Montral and the Universit de Sherbrooke explain how they found ... hormones that are culprits in cancer-prone chronic inflammation diseases such ...
Cached Biology News:Students learn environmental stewardship, improve science scores 2Bacteria provide new insights into human decision making 2Bacteria provide new insights into human decision making 3Bacteria provide new insights into human decision making 4Bacteria provide new insights into human decision making 5Scientists identify natural anti-cancer defenses 2